Retinopathy of prematurity: Understanding ischemic retinal vasculopathies at an extreme of life

Journal of Clinical Investigation

Volumn 120, Issue 9, 2010, Pages 3022-3032

  Sapieha, Przemyslaw ^a,b   Joyal, Jean Sebastien ^c   Rivera, José Carlos ^c   Kermorvant Duchemin, Elsa ^d   Sennlaub, Florian ^d   Hardy, Pierre ^c   Lachapelle, Pierre ^e   Chemtob, Sylvain ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BEVACIZUMAB; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; OXYGEN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; VASCULOTROPIN;

CLINICAL TRIAL; CRYOTHERAPY; EYE BLOOD FLOW; HUMAN; LASER COAGULATION; NEOVASCULARIZATION (PATHOLOGY); NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RETINA DEGENERATION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION;

BLINDNESS; BLOOD VESSELS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; RETINAL DEGENERATION; RETINAL DETACHMENT; RETINAL DISEASES; RETINOPATHY OF PREMATURITY;

EID: 77956354417     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42142     Document Type: Review

References (150)

1. Gibson DL, Sheps SB, Schechter MT, Wiggins S, McCormick AQ. Retinopathy of prematurity: a new epidemic? Pediatrics. 1989;83(4):486-492.
2. Lee SK, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics. 2000;106(5):1070-1079.
3. Phelps DL. Retinopathy of prematurity. N Engl J Med. 1992;326(16):1078- 1080.
4. Dobson V, et al. Color vision measured with pseudoisochromatic plates at five-and-a-half years in eyes of children from the CRYO-ROP study. Invest Ophthalmol Vis Sci. 1996;37(12):2467-2474.
5. Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C, Mercuri-Minich N. School-age outcomes in children with birth weights under 750 g. N Engl J Med. 1994;331(12):753-759.
6. Kushner BJ. Strabismus and amblyopia associated with regressed retinopathy of prematurity. Arch Ophthalmol. 1982;100(2):256-261.
7. Ashton N. Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am J Ophthalmol. 1966;62(3):412-435.
8. McLeod DS, Brownstein R, Lutty GA. Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37(2):300-311.
9. Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1998;39(5):840-845.
10. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36(6):724-731.
11. Roth AM. Retinal vascular development in premature infants. Am J Ophthalmol. 1977;84(5):636-640.
12. Smith LE, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111.
13. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34(3):576-585.
14. Stahl A, et al. Computer-aided quantification of retinal neovascularization. Angiogenesis. 2009;12(3):297-301.
15. Kinsey VE. Cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol. 1956;56(4):481-453.
16. Kinsey VE, et al. PaO2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics. 1977;60(5):655-668.
17. Holmes JM, Zhang S, Leske DA, Lanier WL. Carbon dioxide-induced retinopathy in the neonatal rat. Curr Eye Res. 1998;17(6):608-616.
18. Ajayi OA, Raval D, Lucheese N, Pildes RS. Ophthalmological morbidity in very-low-birthweight infants with bronchopulmonary dysplasia. J Natl Med Assoc. 1997;89(10):679-683.
19. Holmes JM, Leske DA, Zhang S. The effect of raised inspired carbon dioxide on normal retinal vascular development in the neonatal rat. Curr Eye Res. 1997;16(1):78-81.
20. Ehinger B, Falck B. Concomitant adrenergic and parasympathetic fibres in the rat iris. Acta Physiol Scand. 1966;67(2):201-207.
21. Hoste AM, Boels PJ, Andries LJ, Brutsaert DL, De Laey JJ. Effects of beta-antagonists on contraction of bovine retinal microarteries in vitro. Invest Ophthalmol Vis Sci. 1990;31(7):1231-1237.
22. Laties AM. Central retinal artery innervation. Absence of adrenergic innervation to the intraocular branches. Arch Ophthalmol. 1967;77(3):405-409.
23. Guyton AC. The relationship of cardiac output and arterial pressure control. Circulation. 1981;64(6):1079-1088.
24. Alm A, Bill A. The oxygen supply to the retina. II. Effects of high intraocular pressure and of increased arterial carbon dioxide tension on uveal and retinal blood flow in cats. A study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Acta Physiol Scand. 1972;84(3):306-319.
25. Chemtob S, Beharry K, Rex J, Chatterjee T, Varma DR, Aranda JV. Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets. Invest Ophthalmol Vis Sci. 1991;32(6):1799-1807.
26. Hardy P, Nuyt AM, Abran D, St-Louis J, Varma DR, Chemtob S. Nitric oxide in retinal and choroidal blood flow autoregulation in newborn pigs: interactions with prostaglandins. Pediatr Res. 1996;39(3):487-493.
27. Hardy P, Abran D, Li DY, Fernandez H, Varma DR, Chemtob S. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins. Invest Ophthalmol Vis Sci. 1994;35(2):580-591.
28. Riva CE, Grunwald JE, Petrig BL. Autoregulation of human retinal blood flow. An investigation with laser Doppler velocimetry. Invest Ophthalmol Vis Sci. 1986;27(12):1706-1712.
29. Tachibana H, Gotoh F, Ishikawa Y. Retinal vascular autoregulation in normal subjects. Stroke. 1982;13(2):149-155.
30. Milligan DW. Failure of autoregulation and intraventricular haemorrhage in preterm infants. Lancet. 1980;1(8174):896-898.
31. Pryds O, Greisen G, Lou H, Friis-Hansen B. Heterogeneity of cerebral vasoreactivity in preterm infants supported by mechanical ventilation. J Pediatr. 1989;115(4):638-645.
32. Perlman JM, Goodman S, Kreusser KL, Volpe JJ. Reduction in intraventricular hemorrhage by elimination of fluctuating cerebral blood-flow velocity in preterm infants with respiratory distress syndrome. N Engl J Med. 1985;312(21):1353-1357.
33. Yu DY, Cringle SJ, Alder VA, Su EN, Yu PK. Intraretinal oxygen distribution and choroidal regulation in the avascular retina of guinea pigs. Am J Physiol. 1996;270(3 pt 2):H965-H973.
34. Kiel JW, van Heuven WA. Ocular perfusion pressure and choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci. 1995;36(3):579-585.
35. Hardy P, Peri KG, Lahaie I, Varma DR, Chemtob S. Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs. Circ Res. 1996;79(3):504-511.
36. Hardy P, et al. Major role for neuronal NO synthase in curtailing choroidal blood flow autoregulation in newborn pig. J Appl Physiol. 2001;91(4):1655-1662.
37. Kiel JW, Shepherd AP. Autoregulation of choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci. 1992;33(8):2399-2410.
38. Shvedova AA, Alekseeva OM, IYa K, Muranov KO, YuP K, Kagan VE. Damage of photoreceptor membrane lipids and proteins induced by photosensitized generation of singlet oxygen. Curr Eye Res. 1982;2(10):683-689.
39. Abran D, Varma DR, Chemtob S. Increased thromboxane-mediated contractions of retinal vessels of newborn pigs to peroxides. Am J Physiol. 1995;268(2 pt 2):H628-H632.
40. Kulkarni P, Cai J, Hurst HE. Lipids and nitric oxide in porcine retinal and choroidal blood vessels. J Ocul Pharmacol Ther. 2002;18(3):265-275.
41. Kuriyama H, Waki M, Nakagawa M, Tsuda M. Involvement of oxygen free radicals in experimental retinal ischemia and the selective vulnerability of retinal damage. Ophthalmic Res. 2001;33(4):196-202.
42. Siu AW, To CH. Nitric oxide and hydroxyl radical-induced retinal lipid peroxidation in vitro. Clin Exp Optom. 2002;85(6):378-382.
43. Checchin D, et al. PGE(2)-mediated eNOS induction in prolonged hypercapnia. Invest Ophthalmol Vis Sci. 2002;43(5):1558-1566.
44. Giusto NM, Pasquaré SJ, Salvador GA, Castagnet PI, Roque ME, Ilincheta de Boschero MG. Lipid metabolism in vertebrate retinal rod outer segments. Prog Lipid Res. 2000;39(4):315-391.
45. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. 2006;91(5):807-819.
46. Shvedova AA, Alekseeva OM, Kuliev I, Muranov KO, Kozlov Yu P, Kagan VE. Damage of photoreceptor membrane lipids and proteins induced by photosensitized generation of singlet oxygen. Curr Eye Res. 1982;2(10):683-689.
47. Daemen FJ. Vertebrate rod outer segment membranes. Biochim Biophys Acta. 1973;300(3):255-288.
48. Delmelle M. Possible implication of photooxidation reactions in retinal photo-damage. Photochem Photobiol. 1979;29(4):713-716.
49. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992;258(5090):1898-1902.
50. Moncada S, Higgs A, Furchgott R. International union of pharmacology nomenclature in nitric oxide research. Pharmacol Rev. 1997;49(2):137-142.
51. Nielsen JC, Naash MI, Anderson RE. The regional distribution of vitamins E and C in mature and premature human retinas. Invest Ophthalmol Vis Sci. 1988;29(1):22-26.
52. Flynn JT, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326(16):1050-1054.
53. Chemtob S, et al. Peroxide-cyclooxygenase interactions in postasphyxial changes in retinal and choroidal hemodynamics. J Appl Physiol. 1995;78(6):2039-2046.
54. Squadrito GL, Pryor WA. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med. 1998;25(4-5):392-403.
55. Kröncke K-D. Mechanisms and biological consequences of nitrosative stress. Biol Chem. 2003;384(10-11):1341.
56. Beauchamp MH, et al. Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. Free Radic Biol Med. 2004;37(11):1885-1894.
57. Gu X, El-Remessy AB, Brooks SE, Al-Shabrawey M, Tsai N-T, Caldwell RB. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol. 2003;285(3):C546-C554.
58. Brooks SE, et al. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci. 2001;42(1):222-228.
59. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest. 2001;107(6):717-725.
60. Anderson SM, Krinsky NI. Protective action of carotenoid pigments against photodynamic damage to liposomes. Photochem Photobiol. 1973;18(5):403-408.
61. Arstila AU, Smith MA, Trump BF. Microsomal lipid peroxidation: morphological characterization. Science. 1972;175(21):530-533.
62. Kondo T, Kinouchi H, Kawase M, Yoshimoto T. Differential response in the release of hydrogen peroxide between astroglial cells and endothelial cells following hypoxia/reoxygenation. Neurosci Lett. 1996;215(2):103-106.
63. D'Amore PA, Sweet E. Effects of hyperoxia on microvascular cells in vitro. In Vitro Cell Dev Biol. 1987;23(2):123-128.
64. Halks-Miller M, Henderson M, Eng LF. Alpha tocopherol decreases lipid peroxidation, neuronal necrosis, and reactive gliosis in reaggregate cultures of fetal rat brain. J Neuropathol Exp Neurol. 1986;45(4):471-484.
65. Hubel CA, Davidge ST, McLaughlin MK. Lipid hydroperoxides potentiate mesenteric artery vasoconstrictor responses. Free Radic Biol Med. 1993;14(4):397-407.
66. Hemler ME, Cook HW, Lands WE. Prostaglandin biosynthesis can be triggered by lipid peroxides. Arch Biochem Biophys. 1979;193(2):340-345.
67. Beauchamp MH, et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol. 2001;90(6):2279- 2288.
68. Hou X, et al. Augmented vasoconstriction and thromboxane formation by 15-F(2t)-isoprostane (8-iso-prostaglandin F(2alpha)) in immature pig periventricular brain microvessels. Stroke. 2000;31(2):516-524.
69. Morrow JD, et al. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994;269(6):4317-4326.
70. Brault S, et al. Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2alpha: possible role in ischemic brain injury. Stroke. 2003;34(3):776-782.
71. Balazy M, Chemtob S. Trans-arachidonic acids: new mediators of nitro-oxidative stress. Pharmacol Ther. 2008;119(3):275-290.
72. Jiang H, Kruger N, Lahiri DR, Wang D, Vatèle JM, Balazy M. Nitrogen dioxide induces cis-trans-isomerization of arachidonic acid within cellular phospholipids. Detection of trans-arachidonic acids in vivo. J Biol Chem. 1999;274(23):16235-16241.
73. Balazy M. Trans-arachidonic acids: new mediators of inflammation. J Physiol Pharmacol. 2000;51(4 pt 1):597-607.
74. Zghibeh CM, Raj Gopal V, Poff CD, Falck JR, Balazy M. Determination of trans-arachidonic acid isomers in human blood plasma. Anal Biochem. 2004;332(1):137-144.
75. Kermorvant-Duchemin E, et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med. 2005;11(12):1339-1345.
76. Liu L, et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell. 2004;116(4):617-628.
77. Llorens S, Nava E. Cardiovascular diseases and the nitric oxide pathway. Curr Vasc Pharmacol. 2003;1(3):335-346.
78. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 1990;259(5 pt 1):C697-C708.
79. Beauchamp MH, et al. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43(10):3327-3337.
80. Hou X, et al. Increased platelet-activating factor-induced periventricular brain microvascular constriction associated with immaturity. Am J Physiol Regul Integr Comp Physiol. 2003;284(4):R928-R935.
81. Xie Y, Meier KE. Lysophospholipase D and its role in LPA production. Cell Signal. 2004;16(9):975-981.
82. Brault S, et al. Lysophosphatidic acid induces endothelial cell death by modulating the redox environment. Am J Physiol Regul Integr Comp Physiol. 2007;292(3):R1174-R1183.
83. Sapieha P, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14(10):1067-1076.
84. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A. 2000;97(16):9082-9087.
85. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005;2005(306):re12.
86. Flynn JT, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326(16):1050-1054.
87. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-5514.
88. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol. 1998;275(4 pt 1):L818-L826.
89. Chapman-Smith A, Whitelaw ML. Novel DNA binding by a basic helix-loop-helix protein. The role of the dioxin receptor PAS domain. J Biol Chem. 2006;281(18):12535-12545.
90. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev. 2003;17(21):2614-2623.
91. Paul SA, Simons JW, Mabjeesh NJ. HIF at the cross-roads between ischemia and carcinogenesis. J Cell Physiol. 2004;200(1):20-30.
92. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
93. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 1995;77(3):638-643.
94. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90(9):4304-4308.
95. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
96. Kermorvant-Duchemin E, et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol. 2010;120(1):51-60.
97. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49(12):5177-5182.
98. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci. 2002;43(11):3500-3510.
99. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118(2):526-533.
100. Holmes JM, Zhang S, Leske DA, Lanier WL. The effect of carbon dioxide on oxygen-induced retinopathy in the neonatal rat. Curr Eye Res. 1997;16(7):725-732.
101. Simons BD, Flynn JT. Retinopathy of prematurity and associated factors. Int Ophthalmol Clin. 1999;39(2):29-48.
102. Hellstrom A, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98(10):5804-5808.
103. Lofqvist C, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007;104(25):10589-10594.
104. Smith LE, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276(5319):1706-1709.
105. Smith LE, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5(12):1390-1395.
106. Lofqvist C, et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics. 2006;117(6):1930-1938.
107. Firth SM, Baxter RC. Cellular actions of the insulin- like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854.
108. Chen J, Smith LEH. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-140.
109. Lofqvist C, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124(12):1711-1718.
110. Hellstrom A, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123(4):e638-e645.
111. Dorrell MI, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog Retin Eye Res. 2006;25(3):277-295.
112. Fruttiger M, et al. PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron. 1996;17(6):1117-1131.
113. Stone J, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15(7 pt 1):4738-4747.
114. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci. 2002;43(2):522-527.
115. Gariano RF. Cellular mechanisms in retinal vascular development. Prog Retin Eye Res. 2003;22(3):295-306.
116. Dorrell M, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog Retin Eye Res. 2006;25(3):277-295.
117. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp Eye Res. 1997;65(4):555-568.
118. Ramsauer M, D'Amore PA. Getting Tie(2)d up in angiogenesis. J Clin Invest. 2002;110(11):1615-1617.
119. Gerhardt H, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177.
120. Adams RH, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999;13(3):295-306.
121. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev. 2005;16(4-5):535-548.
122. Wilson BD, et al. Netrins promote developmental and therapeutic angiogenesis. Science. 2006;313(5787):640-644.
123. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell. 2009;16(2):209-221.
124. Ishida S, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9(6):781-788.
125. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003;22(6):721-748.
126. Lutty GA, et al. Proceedings of the third international symposium on retinopathy of prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California, USA). Mol Vis. 2006;12:532-580.
127. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci. 2001;42(9):2068-2073.
128. Grant MB, et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res. 1999;85(8):699-706.
129. Mino RP, et al. Adenosine receptor antagonists and retinal neovascularization in vivo. Invest Ophthalmol Vis Sci. 2001;42(13):3320-3324.
130. Gutman M, Bonomi F, Pagani S, Cerletti P, Kroneck P. Modulation of the flavin redox potential as mode of regulation of succinate dehydrogenase activity. Biochim Biophys Acta. 1980;591(2):400-408.
131. Meixner-Monori B, Kubicek CP, Habison A, Kubicek- Pranz EM, Rohr M. Presence and regulation of the alpha-ketoglutarate dehydrogenase multienzyme complex in the filamentous fungus Aspergillus niger. J Bacteriol. 1985;161(1):265-271.
132. Cronstein BN. Adenosine receptors and wound healing. ScientificWorldJournal. 2004;4:1-8.
133. Clark AN, et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res. 2007;101(11):1130-1138.
134. Kvanta A, Seregard S, Sejersen S, Kull B, Fredholm BB. Localization of adenosine receptor messenger RNAs in the rat eye. Exp Eye Res. 1997;65(5):595-602.
135. Checchin D, Sennlaub F, Levavasseur E, Leduc M, Chemtob S. Potential role of microglia in retinal blood vessel formation. Invest Ophthalmol Vis Sci. 2006;47(8):3595-3602.
136. Connor KM, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13(7):868-873.
137. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
138. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24(1):87-138.
139. Gronert K. Lipid autacoids in inflammation and injury responses: a matter of privilege. Mol Interv. 2008;8(1):28-35.
140. Sennlaub F, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108(2):198-204.
141. Engin KN. Alpha-tocopherol: looking beyond an antioxidant. Mol Vis. 2009;15:855-860.
142. Finer NN, Schindler RF, Grant G, Hill GB, Peters K. Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia. A controlled trial. Lancet. 1982;1(8281):1087-1091.
143. Schaffer DB, Johnson L, Quinn GE, Weston M, Bowen FW Jr. Vitamin E and retinopathy of prematurity. Follow-up at one year. Ophthalmology. 1985;92(8):1005-1011.
144. Phelps DL, Rosenbaum AL, Isenberg SJ, Leake RD, Dorey FJ. Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics. 1987;79(4):489-500.
145. Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr. 1997;131(6):844-850.
146. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics. 1988;81(5):697-706.
147. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
148. McLoone E, O'Keefe M, McLoone S, Lanigan B. Long term functional and structural outcomes of laser therapy for retinopathy of prematurity. Br J Ophthalmol. 2006;90(6):754-759.
149. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148(4):536-543 e532.
150. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002;8(9):1004-1010.